DNA Art Online / CC BY-NC-ND 2.0
It reads like an all-caps typo from the technical manual that comes taped to the side of a new refrigerator. But CRISPR is going to change your world. It may even—quite literally—change the face of humanity.
Since its discovery four years ago, the gene-editing system known as “clustered regularly interspaced short palindromic repeats” has been used by scientists to make precise alterations in the DNA sequences of living cells. It offers the prospect of treating (and perhaps even eradicating) debilitating genetic conditions, improving fertility treatments, fighting cancer, and allowing the safe transplantation of tissues and organs between species.
Hemophilia, sickle-cell anemia, and muscular dystrophy are just three of the diseases that could eventually become treatable thanks to therapies developed through CRISPR. In late 2015, for instance, three groups of scientists reported that they could infect muscle cells in living Duchenne muscular dystrophic mice with a virus carrying the CRISPR/Cas9 editing cassette. (The latter alphanumeric term refers to a CRISPR system that employs the Cas9 protein.) The researchers then edited the defective dystrophin gene in enough cells to improve muscle function.
Interestingly, many of the early advances in this technology took place in the yoghurt industry, where scientists were looking to get rid of viral infections in the lactic-acid bacteria that make up industrial cultures.
In 2012, two researchers, Jennifer Doudna and Emmanuelle Charpentier, pulled all the pieces of the CRISPR/Cas9 puzzle together into a functioning module that could guide the scissor-like action of Cas9 to target not just viral DNA, but any specific DNA sequence.
Then, in early 2013, Feng Zhang and George Church published back-to-back papers in the journal Science in which they showed that this process could be made to work in living mammalian cells at a startlingly efficient rate. Genes can be cut, deleted, added to, and altered using mechanisms similar to the editing functions on a word processor.
And so the race began. Scientific reports of new CRISPR/Cas9 uses are now exploding. Gene-editing companies are proliferating. Patent battles are taking shape. And clinical trials for treating diseases using somatic-cell gene editing are underway.
It is impossible to predict what the limits of this technology might be. The time to consider the ethical implications of human germ-line gene editing is now.
Many critics argue that CRISPR-powered techniques aren’t really necessary to prevent the inheritance of destructive genetic conditions. Consider, for example, couples at risk of having children with a disease such as cystic fibrosis. Only one quarter of their embryos will have the two bad genes that lead to CF. These couples can already use in vitro fertilization to produce embryos in a lab and pre-implantation genetic diagnosis to filter out CF-afflicted embryos. (The proposed alternative with CRISPR/Cas9 would be to repair diseased embryos instead of simply destroying them.)
This is where the conversation among scientists and bioethicists turns toward new frontiers that involve human enhancement. How about human babies who are genetically programmed to resist diseases such as HIV? This could probably be done with CRISPR by editing out the receptor for the AIDS virus. Or how about reducing the risk of heart attack? This might be possible by editing out a gene called PCSK9. You can see how we get to a slippery slope. How about muscle mass? Intelligence? Hair colour?
In December 2015, the US National Academy of Sciences, the US National Academy of Medicine, the Chinese Academy of Sciences, and the Royal Society hosted the International Summit on Human Gene Editing in Washington, DC. At the end of this three-day meeting, the twelve-person organizing committee issued a statement asserting that “it would be irresponsible to proceed with any clinical use of germ-line editing unless and until (i) the relevant safety and efficacy issues have been resolved, based on appropriate understanding and balancing of risks, potential benefits, and alternatives, and (ii) there is broad societal consensus about the appropriateness of the proposed application.” (Françoise Baylis was a member of this organizing committee.)
That may initially seem straightforward. But scientists and policy-makers could take radically different approaches to the “balancing of risks, potential benefits, and alternatives.” Even if only a handful of governments, research institutes, and well-funded entrepreneurs press ahead with human germ–line manipulation projects, we will be facing a watershed moment in the genetic development of our species.
To achieve the aforementioned “broad societal consensus,” we must move quickly on this issue at the national and international levels—including here in Canada. The summit’s organizing committee has called for a global discussion involving a wide range of people—not only biomedical scientists, policy-makers, regulators, research funders, and industry representatives, but also health-care providers, patients and their families, people with disabilities, ethicists, lawyers, social scientists, faith leaders, public interest advocates, and members of the general public. And the summit hosts have committed to establishing “a continuing forum for assessment of the many scientific, medical, and ethical questions surrounding the pursuit of human gene-editing
When it comes to editing the human germ line, we need to come together across nations to explore new horizons thoughtfully. More specifically, we need to ask and answer serious questions about what the future might bring. The choices we make today will affect our evolutionary story forever.